Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Crehan

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Neurobiology of Disease|March 5, 2013
Blockage of CR1 prevents activation of rodent microgliaHelen Crehan, John Hardy, Jennifer Pocock
International Journal of Alzheimer'S Disease|September 8, 2012
Microglia, Alzheimer's disease, and complementHelen Crehan, John Hardy, Jennifer Pocock
Molecular Neurodegeneration|July 2, 2016
Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challengesHolger Cynis, Jeffrey L Frost, Helen Crehan, et al.
Immunobiology|August 16, 2011
Complement receptor 1 (CR1) and Alzheimer's diseaseHelen Crehan, Patrick Holton, Selina Wray, et al.
Alzheimer'S Research & Therapy|January 15, 2020
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like miceHelen Crehan, Bin Liu, Martin Kleinschmidt, et al.
Annals of Human Genetics|January 31, 2013
Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk LociPatrick Holton, Mina Ryten, Michael Nalls, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Neurobiology of Disease|March 5, 2013
Blockage of CR1 prevents activation of rodent microgliaHelen Crehan, John Hardy, Jennifer Pocock
International Journal of Alzheimer'S Disease|September 8, 2012
Microglia, Alzheimer's disease, and complementHelen Crehan, John Hardy, Jennifer Pocock
Molecular Neurodegeneration|July 2, 2016
Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challengesHolger Cynis, Jeffrey L Frost, Helen Crehan, et al.
Immunobiology|August 16, 2011
Complement receptor 1 (CR1) and Alzheimer's diseaseHelen Crehan, Patrick Holton, Selina Wray, et al.
Alzheimer'S Research & Therapy|January 15, 2020
Effector function of anti-pyroglutamate-3 Aβ antibodies affects cognitive benefit, glial activation and amyloid clearance in Alzheimer's-like miceHelen Crehan, Bin Liu, Martin Kleinschmidt, et al.
Annals of Human Genetics|January 31, 2013
Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk LociPatrick Holton, Mina Ryten, Michael Nalls, et al.
Pageof 1